Â鶹´«Ã½

The National Institutes of Health (NIH) has long championed the principles of transparency and accessibility in NIH-funded research. To further this commitment, today NIH released a new accelerating broad access to NIH-funded research results. The most significant change from the previous policy is the removal of the 12-month embargo period before manuscripts resulting from NIH funding must be made publicly available. The policy meets the expectations set forth in the White House Office of Science and Technology Policy’s (OSTP) memo .

In addition to the updated policy, NIH has issued supplemental guidance on publication costs and on government use license and rights. The updated policy and supplemental guidance were developed after considering all feedback NIH received on the draft proposals received through a request for information. The revised policy will go into effect for peer-reviewed manuscripts accepted on or after Dec. 31, 2025. Until that time, NIH’s current will remain in effect.

Broadly, the new NIH policy aims to maximize and accelerate access to scientific data and scholarly articles resulting from federal funding, and make research results easier to find and more transparent through the use of metadata and persistent identifiers. These efforts are aligned with the directives of the OSTP memo.

NIH has accomplished the first two objectives through our and updatedÌý Public Access Policy, respectively. For the second objective, today NIH has issued a plan for public comment that will enable researchers, clinicians, students and the public to rapidly locate, contextualize and analyze the results of NIH-supported research.ÌýMore information on this plan and how to provide comments can be found

I would like to thank the White House OSTP for its leadership in this area. The steps taken above reflecr Â鶹´«Ã½â€™s commitment to the responsible stewardship of the nation’s investment in biomedical research by improving transparency and accessibility of taxpayer-funded research.Ìý

Monica M. Bertagnolli, M.D.
Director, NIH

Ìý